Early integration of Design of Experiment (DOE) and multivariate statistics identifies feeding regimens suitable for CHO cell line development and screening

In Chinese Hamster Ovary (CHO) cell lines, the establishment of the ideal fed-batch regimen promotes metabolic conditions advantageous for the bioproduction of therapeutic molecules. A tailored, cell line-specific feeding scheme is typically defined during process development (PD) activities, through the incorporation of Design of Experiment (DOE) and late stage cell culture approaches. The feeding during early stage cell line development (CLD) was a simplified “one-fits-all” design, inherited from PD lab, that didn’t account for CLD needs of throughput and streamlined workflow. The “one-fits-all” efficiency was not routinely verified when novel technologies were incorporated in CLD and sub-optimal feeding carried the risk of not selecting the most desirable cell lines amenable to late stage PD. In our work we developed the DOE-feed method; a streamlined, three-stages framework for identifying efficient feeding schemes as the CLD technologies evolved. We combined early stage cell culture input data with late-stage techniques, such as statistical modelling, principal component analysis (PCA), DOE and Prediction Profiler. Novel in our DOE-feed work, we deliberately anticipated the application of statistics and approached the method development as an early-stage, continuously updated process, by building iterative datasets and statistically interpreting their responses. We capitalized on the statistical models defined by the DOE-feed methodology to study the influence of feeds on daily productivity and growth and to extrapolate feeding-schemes that improved the cell line screening. The DOE-feed became a methodology suited for CLD needs at AbbVie, and optimized the early stage screening, reduced the operational hands-on time and improved the overall workstream efficiency.

[1]  Thomas Ryll,et al.  Maximizing productivity of CHO cell‐based fed‐batch culture using chemically defined media conditions and typical manufacturing equipment , 2010, Biotechnology progress.

[2]  Andrew J Racher,et al.  Rapid high-throughput characterisation, classification and selection of recombinant mammalian cell line phenotypes using intact cell MALDI-ToF mass spectrometry fingerprinting and PLS-DA modelling. , 2014, Journal of biotechnology.

[3]  Jeffrey Ly,et al.  Rapid protein production using CHO stable transfection pools , 2010, Biotechnology progress.

[4]  Alex Eon-Duval,et al.  Application of Quality by Design to the characterization of the cell culture process of an Fc-Fusion protein. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  Nicholas E. Timmins,et al.  Metabolite profiling of CHO cells with different growth characteristics , 2012, Biotechnology and bioengineering.

[6]  Zizhuo Xing,et al.  Feed development for fed‐batch CHO production process by semisteady state analysis , 2009, Biotechnology progress.

[7]  Ashraf Amanullah,et al.  Automated dynamic fed‐batch process and media optimization for high productivity cell culture process development , 2013, Biotechnology and bioengineering.

[8]  Yuansheng Yang,et al.  Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells , 2014, Biotechnology Letters.

[9]  Hervé Broly,et al.  Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality , 2017, Biotechnology and bioengineering.

[10]  Jamey D. Young,et al.  Peak antibody production is associated with increased oxidative metabolism in an industrially relevant fed‐batch CHO cell culture , 2013, Biotechnology and bioengineering.

[11]  H. Broly,et al.  A high-throughput media design approach for high performance mammalian fed-batch cultures , 2013, mAbs.

[12]  Francesc Posas,et al.  Response to Hyperosmotic Stress , 2012, Genetics.

[13]  Hervé Broly,et al.  Tailoring recombinant protein quality by rational media design , 2015, Biotechnology progress.

[14]  Rashmi Kshirsagar,et al.  Advanced process monitoring and feedback control to enhance cell culture process production and robustness , 2015, Biotechnology and bioengineering.

[15]  M. Butler,et al.  Recent advances in technology supporting biopharmaceutical production from mammalian cells , 2012, Applied Microbiology and Biotechnology.

[16]  Gyun Min Lee,et al.  CHO cells in biotechnology for production of recombinant proteins: current state and further potential , 2012, Applied Microbiology and Biotechnology.

[17]  John H. Gauthier,et al.  A general framework for modeling growth and division of mammalian cells , 2011, BMC Systems Biology.

[18]  M. Al‐Rubeai,et al.  The role of the cell cycle in determining gene expression and productivity in CHO cells , 1999, Cytotechnology.

[19]  Miguel A Esteban,et al.  Induced pluripotent stem cell technology in regenerative medicine and biology. , 2010, Advances in biochemical engineering/biotechnology.

[20]  Thomas Gaj,et al.  Expanding the scope of site‐specific recombinases for genetic and metabolic engineering , 2014, Biotechnology and bioengineering.

[21]  Hiroaki Nagashima,et al.  Application of a quality by design approach to the cell culture process of monoclonal antibody production, resulting in the establishment of a design space. , 2013, Journal of pharmaceutical sciences.

[22]  Cleo Kontoravdi,et al.  A framework for the systematic design of fed‐batch strategies in mammalian cell culture , 2014, Biotechnology and bioengineering.

[23]  David E. Ruckerbauer,et al.  What can mathematical modelling say about CHO metabolism and protein glycosylation? , 2017, Computational and structural biotechnology journal.

[24]  Mei Liu,et al.  Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody , 2013, Cytotechnology.

[25]  Andrew J Racher,et al.  An empirical modeling platform to evaluate the relative control discrete CHO cell synthetic processes exert over recombinant monoclonal antibody production process titer , 2011, Biotechnology and bioengineering.

[26]  Kyongbum Lee,et al.  Dynamic model for CHO cell engineering. , 2012, Journal of biotechnology.

[27]  Salim Charaniya,et al.  In pursuit of a super producer-alternative paths to high producing recombinant mammalian cells. , 2007, Current opinion in biotechnology.

[28]  Wenge Wang,et al.  Cell‐controlled hybrid perfusion fed‐batch CHO cell process provides significant productivity improvement over conventional fed‐batch cultures , 2017, Biotechnology and bioengineering.

[29]  Andrew J Racher,et al.  Impact of gene vector design on the control of recombinant monoclonal antibody production by chinese hamster ovary cells , 2011, Biotechnology progress.

[30]  Thomas Ryll,et al.  Development of a scale down cell culture model using multivariate analysis as a qualification tool , 2014, Biotechnology progress.

[31]  Kristi Daris,et al.  Cell line profiling to improve monoclonal antibody production , 2014, Biotechnology and bioengineering.

[32]  Niki S. C. Wong,et al.  A study of monoclonal antibody‐producing CHO cell lines: What makes a stable high producer? , 2009, Biotechnology and bioengineering.

[33]  George Karypis,et al.  Mining manufacturing data for discovery of high productivity process characteristics. , 2010, Journal of biotechnology.

[34]  Andrew J Racher,et al.  Cell line‐specific control of recombinant monoclonal antibody production by CHO cells , 2010, Biotechnology and bioengineering.

[35]  Christina S. Alves,et al.  Integration of cell line and process development to overcome the challenge of a difficult to express protein , 2015, Biotechnology progress.

[36]  Rashmi Kshirsagar,et al.  Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity. , 2016, Journal of biotechnology.

[37]  Andrew J Racher,et al.  Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: Improving the efficiency of cell line generation , 2010, Biotechnology progress.

[38]  Patrick Thompson,et al.  Defining process design space for monoclonal antibody cell culture , 2010, Biotechnology and bioengineering.

[39]  Niraj Kumar,et al.  Proliferation control strategies to improve productivity and survival during CHO based production culture , 2007, Cytotechnology.

[40]  Murray Moo-Young,et al.  Cell cycle phase dependent productivity of a recombinant Chinese hamster ovary cell line , 2007, Cytotechnology (Dordrecht).

[41]  R. Goodacre,et al.  Metabolite profiling of recombinant CHO cells: designing tailored feeding regimes that enhance recombinant antibody production. , 2011, Biotechnology and bioengineering.

[42]  Lin Zhang,et al.  Strategic deployment of CHO expression platforms to deliver Pfizer's Monoclonal Antibody Portfolio , 2017, Biotechnology progress.

[43]  Christel Fenge,et al.  Automation of cell line development , 2009, Cytotechnology.

[44]  Natarajan Vijayasankaran,et al.  Understanding the intracellular effect of enhanced nutrient feeding toward high titer antibody production process , 2011, Biotechnology and bioengineering.

[45]  E. Heinzle,et al.  Macroscopic modeling of mammalian cell growth and metabolism , 2015, Applied Microbiology and Biotechnology.

[46]  Brandon Berry,et al.  Cross‐scale predictive modeling of CHO cell culture growth and metabolites using Raman spectroscopy and multivariate analysis , 2015, Biotechnology progress.

[47]  Brian Glennon,et al.  Revisiting Verhulst and Monod models: analysis of batch and fed-batch cultures , 2015, Cytotechnology.

[48]  Seongkyu Yoon,et al.  Sustaining an efficient and effective CHO cell line development platform by incorporation of 24‐deep well plate screening and multivariate analysis , 2018, Biotechnology progress.

[49]  Scott Estes,et al.  Mammalian cell line developments in speed and efficiency. , 2014, Advances in biochemical engineering/biotechnology.